Scholar Rock announced it will present new clinical and biomarker data from its Phase 1 DRAGON trial of SRK-181 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in November 2024. SRK-181 is an investigational selective inhibitor of latent TGFβ1 activation for advanced solid tumors.
The presentation will share updated safety, efficacy, and biomarker results for SRK-181 in anti-PD-1 resistant patients from the expansion phase (Part B) of the DRAGON trial. This data builds upon previous findings and supports the potential of Scholar Rock's selective approach to inhibiting TGFβ1.
Enrollment for the DRAGON Phase 1 trial was completed in December 2023, with patients continuing on therapy. The presentation at SITC will provide further insights into the durable responses observed in heavily pretreated patients across multiple tumor types.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.